Latest / This Is Why with Dr. Busti
Potassium-Competitive Acid Blockers (PCAB): Pharmacology Made Easy & Clinically Relevant
In this episode of This Is Why, Dr. Busti unpacks the pharmacology and clinical relevance of the potassium-competitive acid blocker (P-CAB) class—featuring vonoprazan, the newest option in acid suppression therapy.
You’ll learn how P-CABs compare to H₂ receptor antagonists and proton pump inhibitors (PPIs) in terms of mechanism, onset, and duration of acid control. Dr. Busti explains the unique pharmacodynamic and pharmacokinetic properties that make vonoprazan a valuable alternative for patients who do not adequately respond to PPIs.
The discussion connects the drug’s molecular action at the…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.